利格列汀

利格列汀（CAS 668270-12-0）的独立参考数据，整理自公开化学数据库。

各数据库的登记标识

计算分子描述符

在册的理化数值

在册的记载用途

Linagliptin is indicated for the treatment of type II diabetes in addition to diet and exercise. It should not be used to treat type I diabetes or in diabetic ketoacidosis. An extended-release combination product containing empagliflozin, linagliptin, and metformin was approved by the FDA in January 2020 for the improvement of glycemic control in adults with type 2 diabetes mellitus when used adjunctively with diet and exercise.Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor which is used in combination with diet and exercise in the therapy of type 2 diabetes, either alone or in combination with other oral hypoglycemic agents. Linagliptin has been linked to rare instances of clinically apparent liver injury.

同义词与商品名

Linagliptin; 668270-12-0; Tradjenta; BI-1356; BI 1356; Trazenta; Trajenta; BI-1356-BS; linagliptine; Linagliptina; BS 1356 BS; BI1356; 3X29ZEJ4R2; BI-1356BS; BI 1356 BS; BS-1356-BS

公开数据库对它的描述

Linagliptin · CAS 668270-12-0 · C25H28N8O2. UNII 3X29ZEJ4R2. Melting Point: 190-196; Melting Point: 202 °C; Solubility: <1 mg/mL.

物理形态与操作说明

数据来源：PubChem / Wikidata；与随货 COA 不一致时以 COA 为准。